Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40
Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
Varian Medical Makes Two Deals in May
Varian Medical Systems (NYSE: VAR) is on the move again. The Palo Alto, California-based medical device maker announced two deals in May 2019 targeting two very different companies. Varian (market cap $11.6 billion) designs, manufactures, sells and services medical devices and software products for treating cancer and other medical conditions. The earlier deal, announced on May 9, brought aboard privately held cardiac ablation firm Cyberheart, based in Sunnyvale, California, for an undisclosed amount. CyberHeart’s intellectual property covers cardiac radioablation, which involves using radiation in the heart and other forms of radiosurgery for certain heart diseases. The second deal,... Read More »
Health Care M&A Deals, Week Ending May 24, 2019
The Health Care M&A Weekly chart is a selection of transactions announced during the prior week(s). The deals presented here are from our Deal Search Online database, which is updated every business day. Visit www.dealsearchonline.com to see how Deal Search Online can help you stay up-to-date on the healthcare market overall, or in a particular sector of interest to your firm. Biotechnology Acquirer Target Price Evotec SE Just Biotherapeutics, Inc. $90,000,000 Merck & Co., Inc. Peloton Therapeutics, Inc. $1,050,000,000 OncoSec Medical Incorporated Portfolio of patents for IL-12 DNA N/A Amgen Inc. Nuevolution $167,000,000 eHealth Acquirer Target Price WELL Health Technologies... Read More »
Advanced Wound Care Firm Acelity Grabbed for $6.7 Billion
3m Company (NYSE: MMM), the global conglomerate, announced in early May it purchased Acelity Inc. for $6.7 billion, or roughly 11.4x EBITDA. The target is a medical device consortium comprised of Apax Partners, affiliates of Canada Pension Plan Investment Board and the Public Sector Pension Investment Board, is selling Acelity. Acelity develops advanced wound care products and specialty surgical applications marketed under the KCI brand name. The company reported a revenue of $1.5 billion in 2018. This acquisition bolsters 3M’s Medical Solutions business and supports its growth strategy to offer comprehensive advanced and surgical wound care solutions. The transaction is expected to... Read More »
Health Carousel Taps into AI
Health Carousel, a healthcare staffing firm with over 1,000 workers under contract, has acquired the digital health platform Lucidity. The target’s technology platform connects physicians seeking part-time or temporary work directly with medical practices looking to fill open shifts, while also using artificial intelligence (AI) technology to help providers and medical practices make better staffing decisions. Lucidity had previously raised funding from Sustineo Ventures. Financial terms were not disclosed. Lucidity will continue to operate as a standalone company under its own brand after the transaction. The business will join the Health Carousel Locums Network (HCLN) as part of... Read More »
Health Care M&A Deals, Week Ending May 17, 2019
The Health Care M&A Weekly chart is a selection of transactions announced during the prior week(s). The deals presented here are from our Deal Search Online database, which is updated every business day. Visit www.dealsearchonline.com to see how Deal Search Online can help you stay up-to-date on the healthcare market overall, or in a particular sector of interest to your firm. Behavioral Health Care Acquirer Target Price Swanton Care & Community Values in Care Ltd and GRS Care Ltd N/A Kadiant Central Valley Autism Project N/A eHealth Acquirer Target Price Health Carousel Lucidity N/A MiraMed Global Services LLC Medac, Inc N/A Discovery Health Partners... Read More »
Autism Therapy Provider Hopebridge Changes Hands Again
Autism treatment companies are still hot targets in 2019. Eight transactions have been announced so far this year, compared with 20 in all of 2018. (That was an outsized year for every healthcare sector. There were nine deals for autism targets in 2017.) Private equity firms are trading platforms in this sub-sector. Just this year, Gryphon Investors bought Learn Behavioral from LLR Partners for an undisclosed amount. Now there’s the deal between Baird Capital and Arsenal Capital Partners for Hopebridge LLC. Hopebridge LLC was launched in 2005 in Indianapolis, Indiana to serve the growing need for autism treatment services. The clinic-based autism therapy business provides Applied... Read More »
Oak Hill Capital Exits AccentCare
May has been a busy month for deals in the Home Health & Hospice sector with eight transactions announced midway through the month. The latest is Oak Hill Capital Partners’ sale of its post-acute care platform, AccentCare, Inc. to Advent International. Financial terms were not disclosed. Today, AccentCare is the sixth largest home health platform and the third largest personal care platform in the United States. It serves health systems, physician practices and managed care organizations, and includes strategic joint ventures and partnerships. Its range of services includes personal, non-medical care to skilled nursing, rehabilitation, hospice care and care management. Oak Hill... Read More »
Health Care M&A Deals, Week Ending May 10, 2019
The Health Care M&A Weekly chart is a selection of transactions announced during the prior week(s). The deals presented here are from our Deal Search Online database, which is updated every business day. Visit www.dealsearchonline.com to see how Deal Search Online can help you stay up-to-date on the healthcare market overall, or in a particular sector of interest to your firm. Behavioral Health Care Acquirer Target Price Perimeter Healthcare 2 Sundance pyschiatric hospitals N/A Arsenal Capital Partners Hopebridge LLC N/A Biotechnology Acquirer Target Price Pfizer Inc. Therachon Holding AG $340,000,000 eHealth Acquirer Target Price Harris... Read More »
Xiidra, Dry Eye Treatment Drug, Acquired by Novartis
The global pharmaceutical giant Novartis (NYSE: NVS) bought the assets to Xiidra 5% solution from Takeda Pharmaceutical Company (NYSE: TAK). The announcement gives us the largest pharmaceutical deal of the year so far, with Novartis paying $3.4 billion upfront and $1.9 billion in potential milestones for the drug. In 2018, Xiidra generated revenue of $400 million. Xiidra is the first and only prescription treatment approved for both signs and symptoms of dry eye by inhibiting inflammation caused by the disease. This acquisition fits strategically within Novartis’ ophthalmic pharmaceutical portfolio, laying the groundwork for front-of-the-eye pipeline products currently in... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
